BioCardia, Inc. 8-K

What Happened
BioCardia, Inc. (BCDA) reported on Form 8‑K (filed March 17, 2026) that the U.S. Food and Drug Administration has accepted its pre‑submission package for the Helix Transendocardial Delivery Catheter. The Helix is intended for intramyocardial delivery of therapeutic and diagnostic agents. The company issued a press release about the acceptance, which is attached as Exhibit 99.1 to the 8‑K.

Key Details

• FDA acceptance of BioCardia’s pre‑submission package for the Helix device announced on March 17, 2026.
• Device name: Helix Transendocardial Delivery Catheter (for intramyocardial therapeutic and diagnostic agent delivery).
• Announcement made via company press release, filed as Exhibit 99.1 to the Form 8‑K (Item 8.01).

Why It Matters
This is a regulatory milestone indicating BioCardia has engaged the FDA on the Helix device and submitted materials for initial FDA feedback. For investors, acceptance of a pre‑submission does not mean approval but signals progress in the regulatory process for a product that could be central to the company’s future clinical and commercialization plans. Track subsequent regulatory filings and company updates for further developments.